Freestone Grove Partners LP Neurocrine Biosciences Inc Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 132,338 shares of NBIX stock, worth $19.2 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
132,338
Previous 168,133
21.29%
Holding current value
$19.2 Million
Previous $21.1 Billion
12.09%
% of portfolio
0.14%
Previous 0.16%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
725Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...